# EDGAR Filing Document

**Accession Number:** 0001581178
**File Stem:** 0001193125-25-209033
**Filing Date:** 2025-9
**Character Count:** 4192
**Document Hash:** f36e3910d1f3d66d33921fb862ca3651
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-209033.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001193125-25-209033

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250919

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUPRAXIA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001581178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41923
- **FILM NUMBER:** 251326713

**BUSINESS ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
- **BUSINESS PHONE:** 250-590-3968

**MAIL ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of February 2025** 

**Commission File Number: 001-41923** 

## Eupraxia Pharmaceuticals Inc.
**(Translation of registrant's name into English)** 

**201-2067 Cadboro Bay Road** 

**Victoria, British Columbia, Canada V8R 5G4** 

**Telephone : (250) 590-3968** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

------

**DOCUMENTS INCLUDED AS PART OF THIS REPORT** 

---

| | |
|:---|:---|
| **Exhibit** |  |
| 99.1 | [Material Change Report of the Registrant, dated February 20, 2025](d82327dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **Eupraxia Pharmaceuticals Inc..** |
|  | (Registrant) |
| Date: September 19, 2025 | /s/ Alex Rothwell |
|  | Alex Rothwell |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**FORM 51-102F3** 

***MATERIAL CHANGE REPORT***

---

| | |
|:---|:---|
| **Item 1:** | **Name and Address of Company**  |

---

Eupraxia Pharmaceuticals Inc. (the "**Company**")

201-2067 Cadboro Bay Rd.

Victoria, British Columbia

Canada, V8R 5G4

---

| | |
|:---|:---|
| **Item 2:** | **Date of Material Change**  |

---

February 18, 2025

---

| | |
|:---|:---|
| **Item 3:** | **News Release**  |

---

A news release announcing the material change was issued on February 18, 2025 through Globe Newswire and a copy was subsequently filed on SEDAR+.

---

| | |
|:---|:---|
| **Item 4:** | **Summary of Material Change**  |

---

On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company's new Chief Financial Officer ("**CFO**"), effective immediately.

---

| | |
|:---|:---|
| **Item 5.1:** | **Full Description of Material Change**  |

---

On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company's new CFO, effective immediately.

Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.

---

| | |
|:---|:---|
| **Item 5.2:** | **Disclosure of Restructuring Transactions**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 6:** | **Reliance on subsection 7.1(2) of National Instrument 51-102**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 7:** | **Omitted Information**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 8:** | **Executive Officer**  |

---

For further information, please contact James A. Helliwell, Chief Executive Officer of the Company at 250-590-3968.

---

| | |
|:---|:---|
| **Item 9:** | **Date of Report**  |

---

February 20, 2025